Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US9144559
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
US10022447
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
US8945620
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) |
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic